Rulonilimab clinical trials
How each study uses rulonilimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the rulonilimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
9 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses rulonilimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)RecruitingPhase 2/3Shandong New Time Pharmaceutical Co., LTDNCT07761429Written as F520 combined with chemotherapy
- A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical CancerEnrolling by invitationPhase 2/3Shandong New Time Pharmaceutical Co., LTDNCT06755515Written as Rulonilimab
- the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular CarcinomaRecruitingPhase 2/3Shandong New Time Pharmaceutical Co., LTDNCT05408221Written as Rulonilimab+Lenvatinib
- A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Status unknownPhase 2Shandong New Time Pharmaceutical Co., LTDNCT05741021Written as F520
- Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid TumorsStatus unknownPhase 1/2Shandong New Time Pharmaceutical Co., LTDNCT05740215Written as F520
- A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCLStatus unknownPhase 2Shandong New Time Pharmaceutical Co., LTDNCT05178836Written as F520+F007
- A Phase Ⅱ Study of F520 in Patients With Urothelial CarcinomaStatus unknownPhase 2Shandong New Time Pharmaceutical Co., LTDNCT04636515Written as F520
- The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).Status unknownPhase 2Shandong New Time Pharmaceutical Co., LTDNCT04457830Written as F520
- A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)Status unknownPhase 2Shandong New Time Pharmaceutical Co., LTDNCT04457869Written as F520
Codes
What other systems call rulonilimab · ClinicalTrials.gg INT017085
- UNII (FDA) KQA6N2NT4ZRULONILIMABOne source FDA
- NCI Thesaurus C162636RulonilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | KQA6N2NT4Z | RULONILIMAB | One source FDA |
| NCI Thesaurus | C162636 | Rulonilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.